Houghton A N, Meyers M L, Chapman P B
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Surg Clin North Am. 1996 Dec;76(6):1343-54. doi: 10.1016/s0039-6109(05)70519-3.
The role of combination chemotherapy in the treatment of metastatic melanoma is still a matter of controversy because of the lack of prospective trials directly demonstrating increased response rates and improved survival compared with DTIC alone. Nevertheless, several three-drug regimens have reported response rates between 30% and 50% in single-institution studies. The duration of response medians of these regimens ranges between 6 and 9 months. However, the survival medians of 6 to 11 months are not substantially better than those of DTIC alone. However, survival at 1 and 2 years following initiation of therapy may more clearly demonstrate an impact of therapies for metastatic melanoma.
由于缺乏直接证明与单用达卡巴嗪（DTIC）相比联合化疗能提高缓解率和改善生存率的前瞻性试验，联合化疗在转移性黑色素瘤治疗中的作用仍存在争议。尽管如此，在单机构研究中，几种三联疗法的缓解率报告在30%至50%之间。这些疗法的缓解持续时间中位数在6至9个月之间。然而，6至11个月的生存中位数并不比单用DTIC有显著改善。不过，治疗开始后1年和2年的生存率可能更能清楚地显示转移性黑色素瘤治疗的效果。
